Protagonist Therapeutics, Inc

Protagonist Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing targeted oral and injectable therapeutics for gastrointestinal and systemic disorders. The company's most advanced program, Icotyde, is a first-in-class targeted oral peptide in clinical development for moderate-to-severe plaque psoriasis in adult and pediatric patients aged 12 and older. Rusfertide, a hepcidin mimetic administered via injection, is in Phase 3 development for polycythemia vera, a rare blood disorder characterized by elevated red blood cell production.

The company maintains a pipeline of earlier-stage candidates addressing multiple therapeutic areas. PN-881, an oral interleukin-17 antagonist, is in Phase 1 trials for immune-mediated skin diseases. Development candidates PN-477 and PN-458 target obesity, while PN-8047 represents an orally administered small molecule hepcidin mimetic. The company is also developing an L-4R alpha antagonist for atopic dermatitis and moderate-to-severe asthma, alongside amylinR-based agonists in both oral and subcutaneous formulations for obesity treatment.

Protagonist Therapeutics operates with approximately 132 full-time employees and maintains headquarters in Newark, California. The company is incorporated in Delaware and trades on the Nasdaq exchange. As a clinical-stage entity, the company does not currently generate revenue from product sales, with financial support dependent on capital raises and potential milestone payments from partnerships.